Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases

The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.

Automated summary

The activity of KRAS inhibitors against brain metastases is not well studied. Recent preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial suggest that adagrasib (MRTX849) has the potential to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.